Regulus Therapeutics Competitors

Amgen (NASDAQ:AMGN) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Amgen and Regulus Therapeutics' gross revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Amgen and Regulus Therapeutics, as reported by MarketBeat.

Amgen currently has a consensus price target of $261.1429, indicating a potential upside of 2.44%. Regulus Therapeutics has a consensus price target of $1.25, indicating a potential upside of 4.17%. Given Regulus Therapeutics' higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than Amgen.

Profitability

This table compares Amgen and Regulus Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.

Summary

Amgen beats Regulus Therapeutics on 10 of the 14 factors compared between the two stocks.

Regulus Therapeutics (NASDAQ:RGLS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Regulus Therapeutics and Gilead Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Regulus Therapeutics and Gilead Sciences, as reported by MarketBeat.com.

Regulus Therapeutics currently has a consensus target price of $1.25, indicating a potential upside of 4.17%. Gilead Sciences has a consensus target price of $97.92, indicating a potential upside of 48.30%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Regulus Therapeutics.

Insider and Institutional Ownership

20.0% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 18.2% of Regulus Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Regulus Therapeutics has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Earnings and Valuation

This table compares Regulus Therapeutics and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Regulus Therapeutics on 11 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Vertex Pharmaceuticals and Regulus Therapeutics, as provided by MarketBeat.

Vertex Pharmaceuticals currently has a consensus price target of $293.1250, indicating a potential upside of 31.85%. Regulus Therapeutics has a consensus price target of $1.25, indicating a potential upside of 4.17%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Regulus Therapeutics.

Profitability

This table compares Vertex Pharmaceuticals and Regulus Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Regulus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Regulus Therapeutics on 13 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Regulus Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Regulus Therapeutics, as provided by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus target price of $646.2609, indicating a potential upside of 28.02%. Regulus Therapeutics has a consensus target price of $1.25, indicating a potential upside of 4.17%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Regulus Therapeutics.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Regulus Therapeutics' revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Regulus Therapeutics on 12 of the 15 factors compared between the two stocks.

Regulus Therapeutics (NASDAQ:RGLS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Risk and Volatility

Regulus Therapeutics has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings and Valuation

This table compares Regulus Therapeutics and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regulus Therapeutics and Biogen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Regulus Therapeutics and Biogen, as reported by MarketBeat.com.

Regulus Therapeutics currently has a consensus target price of $1.25, suggesting a potential upside of 4.17%. Biogen has a consensus target price of $303.3103, suggesting a potential upside of 12.80%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Regulus Therapeutics.

Institutional and Insider Ownership

20.0% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 18.2% of Regulus Therapeutics shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biogen beats Regulus Therapeutics on 10 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alexion Pharmaceuticals and Regulus Therapeutics, as provided by MarketBeat.

Alexion Pharmaceuticals currently has a consensus price target of $153.4286, suggesting a potential downside of 7.19%. Regulus Therapeutics has a consensus price target of $1.25, suggesting a potential upside of 4.17%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than Alexion Pharmaceuticals.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Regulus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Regulus Therapeutics' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Regulus Therapeutics on 10 of the 15 factors compared between the two stocks.